Update on Stenotrophomonas maltophilia infection in the ICU

Clinical Pulmonary Medicine

Volumn 14, Issue 1, 2007, Pages 17-22

  Mendoza, Diego Lopez ^a   Darin, Michael ^b   Waterer, Grant W ^c   Wunderink, Richard G ^b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

lactamase; Antibiotic resistance; Efflux pumps; Nosocomial infection; Stenotrophomonas maltophilia

Indexed keywords

AMINOGLYCOSIDE; AZTREONAM; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GATIFLOXACIN; GLYCYLCYCLINE DERIVATIVE; GREPAFLOXACIN; LEVOFLOXACIN; MINOCYCLINE; MOXIFLOXACIN; NORFLOXACIN; POLYMYXIN B; QUINOLONE DERIVATIVE; RUFLOXACIN; TETRACYCLINE; TIMENTIN; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CLINICAL FEATURE; DISEASE SEVERITY; DRUG MECHANISM; DRUG PREFERENCE; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INTENSIVE CARE UNIT; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; STENOTROPHOMONAS MALTOPHILIA; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 33846269683     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000252835.11240.42     Document Type: Review

References (85)

1. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998;11:57-80.
2. Palleroni NJ, Bradbury JF. Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia (Hugh 1980) Swings et al. 1983. Int J Syst Bacteriol. 1993;43:606-609.
3. Gales AC, Jones RN, Forward KR, et al. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis. 2001;32(Suppl 2):S104-S113.
4. Marshall WF, Keating MR, Anhalt JP, et al. Xanthomonas maltophilia: an emerging nosocomial pathogen. Mayo Clin Proc. 1989;64:1097-1104.
5. VanCouwenberghe CJ, Farver TB, Cohen SH. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect Control Hosp Epidemiol. 1997;18:316-321.
6. Vartivarian SE, Papadakis KA, Palacios JA, et al. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum. Ann Intern Med. 1994;121:969-973.
7. Calza L, Manfredi R, Chiodo F. Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: a 10-year surveillance study. Infection. 2003;31:155-161.
8. Heath T, Currie B. Nosocomial and community-acquired Xanthomonas maltophilia infection in tropical Australia. J Hosp Infect. 1995;30:309-313.
9. Schaumann R, Stein K, Eckhardt C, et al. Infections caused by Stenotrophomonas maltophilia - a prospective study. Infection. 2001;29:205-208.
10. Gopalakrishnan R, Hawley HB, Czachor JS, et al. Stenotrophomonas maltophilia infection and colonization in the intensive care units of two community hospitals: a study of 143 patients. Heart Lung. 1999;28:134-141.
11. Muder RR, Yu VL, Dummer JS, et al. Infections caused by Pseudomonas maltophilia. Expanding clinical spectrum. Arch Intern Med. 1987;147:1672-164.
12. Friedman ND, Korman TM, Fairley CK, et al. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect. 2002;45:47-53.
13. Muder RR, Harris AP, Muller S, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996;22:508-512.
14. Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect. 1995;30(Suppl):453-464.
15. Senol E, DesJardin J, Stark PC, et al. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis. 2002;34:1653-1656.
16. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug resistant bacteria. Am J Respir Crit Care Med. 1998;157:531-539.
17. Pathmanathan A, Waterer GW. Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection. Eur Respir J. 2005;25:911-914.
18. Hanes SD, Demirkan K, Tolley E, et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis. 2002;35:228-235.
19. Ibrahim EH, Ward S, Sherman G, et al. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest. 2000;117:1434-1442.
20. Edmond MB, Riddler SA, Baxter CM, et al. Agrobacterium radiobacter: a recently recognized opportunistic pathogen. Clin Infect Dis. 1993;16:388-391.
21. Janda JM, Abbott SL. Evolving concepts regarding the genus Aeromonas: an expanding panorama of species, disease presentations, and unanswered questions. Clin Infect Dis. 1998;27:332-344.
22. Wishart MM, Riley TV. Infection with Pseudomonas maltophilia hospital outbreak due to contaminated disinfectant. Med J Aust. 1976;2:710-712.
23. Vanholder R, Vanhaecke E, Ringoir S. Pseudomonas septicemia due to deficient disinfectant mixing during reuse. Int J Artif Organs. 1992;15:19-24.
24. Dignani MC, Grazziutti M, Anaissie E. Stenotrophomonas maltophilia infections. Semin Respir Crit Care Med. 2003;24:89-98.
25. Carsenti-Etesse H, Durant J, Entenza J, et al. Effects of subinhibitory concentrations of vancomycin and teicoplanin on adherence of staphylococci to tissue culture plates. Antimicrob Agents Chemother. 1993;37:921-923.
26. De Vidipo LA, De Marques EA, Puchelle E, et al. Stenotrophomonas maltophilia interaction with human epithelial respiratory cells in vitro. Microbiol Immunol. 2001;45:563-569.
27. Elvers KT, Leeming K, Lappin-Scott HM. Binary culture biofilm formation by Stenotrophomonas maltophilia and Fusarium oxysporum. J Ind Microbiol Biotechnol. 2001;26:178-183.
28. Jucker BA, Harms H, Zehnder AJ. Adhesion of the positively charged bacterium Stenotrophomonas (Xanthomonas) maltophilia 70401 to glass and Teflon. J Bacteriol. 1996;178:5472-5479.
29. Elting LS, Bodey GP. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine (Baltimore). 1990;69:296-306.
30. Elting LS, Khardori N, Bodey GP, et al. Nosocomial infection caused by Xanthomonas maltophilia: a case control study of predisposing factors. Infect Control Hosp Epidemiol. 1990;11:134-138.
31. Khardori N, Elting L, Wong E, et al. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis. 1990;12:997-1003.
32. Raffenberg M, Szymanski T, Lubasch A, et al. Infections caused by Stenotrophomonas maltophilia (SMA) in intensive care patients - a prospective case-control study. Dtsch Med Wochenschr. 2001;126:514-518.
33. Sanyal SC, Mokaddas EM. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother. 1999;11:28-33.
34. Krcmery V Jr, Pichna P, Oravcova E, et al. Stenotrophomonas maltophilia bacteraemia in cancer patients: report on 31 cases. J Hosp Infect. 1996;34:75-77.
35. Franzetti F, Cernuschi M, Esposito R, et al. Pseudomonas infections in patients with AIDS and AIDS-related complex. J Intern Med. 1992;231:437-443.
36. Micozzi A, Venditti M, Monaco M, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis. 2000;31:705-711.
37. Julve R, Rovira E, Belda A, et al. Clinical manifestations of Stenotrophomas (Xanthomonas) maltophilia infection. An Med Interna. 1998;15:476-480.
38. Villarino ME, Stevens LE, Schable B, et al. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol. 1992;13:201-206.
39. Crowder MW, Walsh TR, Banovic L, et al. Overexpression, purification, and characterization of the cloned metallo-beta-lactamase L1 from Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 1998;42:921-926.
40. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis. 1998;27(Suppl 1):S93-S99.
41. Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol. 2001;3:255-264.
42. Pradhananga SL, Rowling PJ, Simpson IN, et al. Sensitivity of L-2 type beta-lactamases from Stenotrophomonas maltophilia to serine active site beta-lactamase inhibitors. J Antimicrob Chemother. 1996;37:394-396.
43. Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother. 2000;44:287-293.
44. Alonso A, Martinez JL. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 1997;41:1140-1142.
45. Alonso A, Martinez JL. Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2001;45:1879-1881.
46. Alonso A, Martinez JL. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2000;44:3079-3086.
47. Valdezate S, Vindel A, Echeita A, et al. Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility. Antimicrob Agents Chemother. 2002;46:665-671.
48. Zhang L, Li WZ, Poole K. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. J Antimicrob Chemother. 2001;48:549-552.
49. Nseir S, Di Pompeo C, Soubrier S, et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med. 2005;33:283-289.
50. Hendricks O, Butterworth TS, Kristiansen JE. The in-vitro antimicrobial effect of non-antibiotics and putative inhibitors of efflux pumps on Pseudomonas aeruginosa and Staphylococcus aureus. Int J Antimicrob Agents. 2003;22:262-264.
51. Schweizer HP. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. Genet Mol Res. 2003;2:48-62.
52. Spangler SK, Visalli MA, Jacobs MR, et al. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to cipro-floxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole and imipenem. Antimicrob Agents Chemother. 1996;40:772-775.
53. Traub WH, Leonhard B, Bauer D. Antibiotic susceptibility of Stenotrophomonas (Xanthomonas) maltophilia: comparative (NCCLS criteria) evaluation of antimicrobial drugs with the agar dilution and the agar disk diffusion (Bauer-Kirby) tests. Chemotherapy. 1998;44:164-173.
54. Vartivarian S, Anaissie E, Bodey G, et al. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother. 1994;38:624-627.
55. Liaw SJ, Teng LJ, Hsueh PR, et al. In vitro activities of antimicrobial combinations against clinical isolates of Stenotrophomonas maltophilia. J Formos Med Assoc. 2002;101:495-501.
56. Kollef MH, Silver P, Murphy DM, et al. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest. 1995;108:1655-1662.
57. Laing FP, Ramotar K, Read RR, et al. Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J Clin Microbiol. 1995;33:513-518.
58. Liaw YS, Yang PC, Wu ZG, et al. The bacteriology of obstructive pneumonitis. A prospective study using ultrasound-guided transthoracic needle aspiration. Am J Respir Crit Care Med. 1994;149:1648-1653.
59. Yousem SA. Graft eosinophilia in lung transplantation. Hum Pathol. 1992;23:1172-1177.
60. Denton M, Wilcox MH. Antimicrobial treatment of pulmonary colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients. J Antimicrob Chemother. 1997;40:468-474.
61. Jang TN, Wang FD, Wang LS, et al. Xanthomonas maltophilia bacteremia: an analysis of 32 cases. J Formos Med Assoc. 1992;91:1170-1176.
62. Betriu C, Sanchez A, Palau ML, et al. Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993-1999. J Antimicrob Chemother. 2001;48:152-154.
63. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents. 2005;25:95-109.
64. Weiss K, Restieri C, De Carolis E, et al. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother. 2000;45:363-365.
65. Bonfiglio G, Cascone C, Azzarelli C, et al. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother. 2000;45:115-117.
66. Lanzafame A, Bonfiglio C, Santini L, et al. In vitro activity of levofloxacin against recent Gram-negative nosocomial pathogens. Chemotherapy. 2005;51:44-50.
67. Giamarellos-Bourboulis EJ, Karnesis L, Galani I, et al. In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother. 2002;46:3997-3999.
68. Rolston KV, Vaziri I, Frisbee-Hume S, et al. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients. Chemotherapy. 2004;50:214-220.
69. Sheng WH, Wang JT, Chen YC, et al. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan. J Microbiol Immunol Infect. 2001;34:178-184.
70. Ba BB, Feghali H, Arpin C, et al. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother. 2004;48:946-953.
71. Di Bonaventura G, Spedicato I, D'Antonio D, et al. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother. 2004;48:151-160.
72. Betriu C, Rodriguez-Avial I, Sanchez BA, et al. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother. 2002;46:892-895.
73. Betriu C, Rodriguez-Avial I, Sanchez BA, et al. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother. 2002;50:758-759.
74. Zelenitsky SA, Iacovides H, Ariano RE, et al. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis. 2005;51:39-43.
75. Kataoka D, Tanaka Y. The combination of aztreonam and cefozopran against Stenotrophomonas maltophilia. J Infect Chemother. 2004;10:62-64.
76. Krueger TS, Clark EA, Nix DE. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis. 2001;41:71-78.
77. Fang FC, Madinger NE. Resistant nosocomial gram-negative bacillary pathogens: Acinetobacter baumannii, Xanthomonas maltophilia, and Pseudomonas cepacia. Curr Clin Top Infect Dis. 1996;16:52-83.
78. Gruson D, Hilbert G, Vargas F, et al. Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gramnegative bacteria. Am J Respir Crit Care Med. 2000;162(3 Pt 1):837-843.
79. Kollef MH, Vlasnik J, Sharpless L, et al. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med. 1997;156(4 Pt 1):1040-1048.
80. Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet. 1994;344(8933):1329-1332.
81. Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis. 1999;28:1062-1066.
82. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998;280:1233-1237.
83. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med. 2000;132:621-630.
84. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162:505-511.
85. Alvarez-Lerma F, Gasulla Guillermo M, Abad Peruga V, et al. Effectiveness of contact isolation in the control of multiresistant bacteria in an intensive care service. Enf Inf Micr Clin. 2002;20:57-63.